Original Articles

Horizon Scanning of Oncology Drugs in Iran in 2015


 Background: Healthcare horizon scanning systems, have become one of the main components of health technology assessment. We conducted a horizon scanning exercise to identify new oncology drugs that may have a high impact on cancer patients and the health system in Iran.Methods: We reviewed existing health technology horizon scanning systems, and selected and weighted criteria for prioritizing oncology drugs, including 1) clinical efficiency and effectiveness, 2) incidence and prevalence of cancer types, 3) potential costs, 4) availability of alternative treatment, 5) having variable indications, 6) quality of evidence, and 7) being a first, second or third line drug. We reviewed horizon scanning reports in other countries and prepared a list of new oncology drugs to be ranked. We summarized clinical and epidemiological information about the drugs and presented them to a member of our expert panel who ranked them based on a structured checklist. Eventually, the drugs were categorized into four groups from low to high impact, based on their effect on patients and the health system of Iran in the futureResults: We identified 158 new oncology drugs, most of which were in their phase III clinical trials, and had been approved by the US Food and Drug Administration (FDA). Finally, we selected 18 medicines as having the highest impact on patients and the health system of Iran.Conclusion: The results of this study can be used for several purposes, including research and drug development. These results suggest the need for periodical horizon scanning in Iran and other low and middle-income countries. 

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. International journal of cancer. 2015;136(5).

Stewart B, Wild CP. World cancer report 2014. Health. 2017.

Daroudi R, Mirzania M, Zendehdel K. Attitude of Iranian medical oncologists toward economic aspects, and policy-making in relation to new cancer drugs. International journal of health policy and management. 2016;5(2):99.

Shih Y-CT, Smieliauskas F, Geynisman DM, Kelly RJ, Smith TJ. Trends in the cost and use of targeted cancer therapies for the privately insured nonelderly: 2001 to 2011. Journal of Clinical Oncology. 2015;33(19):2190-6.

Glode AE, May MB. Rising Cost of Cancer Pharmaceuticals: Cost Issues and Interventions to Control Costs. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2017;37(1):85-93.

Vogler S, Vitry A. Cancer drugs in 16 European countries, Australia, and New Zealand: a cross-country price comparison study. The Lancet Oncology. 2016;17(1):39-47.

Sullivan SD, Watkins J, Sweet B, Ramsey SD. Health technology assessment in health-care decisions in the United States. Value in Health. 2009;12:S39-S44.

Daniels N, Porteny T, Urritia J. Expanded HTA: enhancing fairness and legitimacy. International journal of health policy and management. 2016;5(1):1.

Packer C, Simpson S, de Almeida RT. EUROSCAN International Network Member Agencies: their structure, processes, and outputs. International journal of technology assessment in health care. 2015;31(1-2):78-85.

Simpson S. A toolkit for the identification and assessment of new and emerging health technologies. 2014.

Sun F, Schoelles K. A systematic review of methods for health care technology horizon scanning (Prepared by ECRI Institute under Contract No. 290-2010-00006-C.) AHRQ Publication No. 13-EHC104-EF, 2013.

Mobinizadeh M, Raeissi P, Nasiripour AA, Olyaeemanesh A, Tabibi SJ. The health systems' priority setting criteria for selecting health technologies: A systematic review of the current evidence. Medical journal of the Islamic Republic of Iran. 2016;30:329.

Migliore A, Perrini MR, Jefferson T, Cerbo M. Implementing a national early awareness and alert system for new and emerging health technologies in Italy: the COTE Project. International journal of technology assessment in health care. 2012;28(3):321-6.

Wild C, Simpson S, Douw K, Geiger-Gritsch S, Mathis S, Langer T. Information service on new and emerging health technologies: Identification and prioritization processes for a European Union–wide newsletter. International journal of technology assessment in health care. 2009;25(S2):48-55.

Gutierrez-Ibarluzea I, Simpson S, Benguria-Arrate G. Early awareness and alert systems: an overview of EuroScan methods. International journal of technology assessment in health care. 2012;28(3):301-7.

Packer C, Fung M, Stevens A. Analyzing 10 years of early awareness and alert activity in the United kingdom. International journal of technology assessment in health care. 2012;28(3):308-14.

Douw K, Vondeling H, Oortwijn W. Priority setting for horizon scanning of new health technologies in Denmark: Views of health care stakeholders and health economists. Health policy. 2006;76(3):334-45.

IssueVol 9 No 2 (2017) QRcode
SectionOriginal Articles
Horizon Scanning Cancer Oncology Drugs Iran

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
Hosseini B, Daroudi R, Mirzania M, Vaezi M, Shahi F, Kalaghchi B, Mobinizadeh M, Rashidian H, Hamouzadeh P, Zendehdel K. Horizon Scanning of Oncology Drugs in Iran in 2015. Basic Clin Cancer Res. 2018;9(2):29-37.